Company profile
Zeo ScientifiX, Inc.
OTC: ZEOX · Healthcare · Biotechnology
#702 of 1,418 Healthcare companies by revenue59th-percentile growth
EA Score
43DFH 39DQ 53GM 32SS 45
v0.1 · 65/100 weight · provisional
↑ disclosure history, Piotroski F · ↓ growth stability, return on assets
Methodology →Revenue TTM
$7.0M
Rev growth YoY (TTM)
+52.8%
Net income (FY)
-$5.5M
Employees
20
as of 2026-08-22
Market cap
$12.3M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.2M$5.2M2024
Net income-$5.5M-$5.5M2024
Operating income-$5.4M-$5.4M2024
Total assets$1.5M$1.5M2024
Liabilities$3.0M$3.0M2024
Equity-$1.4M-$1.4M2024
Revenue trend
FY2018 – FY2024 · USD
FY18
FY20
FY20
FY21
FY22
FY23
FY24
FY24
Revenue by segment
Filed disclosures · FY2018
By product
Patient Referral and Product Sales100%
MMTC Activities0%
By geography
Not disclosed.
The read
What is Zeo ScientifiX, Inc.’s revenue?
Zeo ScientifiX, Inc. booked $5.2M in FY2024 revenue, growing 13% year over year — about the middle of the pack among Healthcare companies we track, at a -106.2% net margin.
Peers · Healthcare
Targeted Medical Pharma, Inc.——Plus Therapeutics, Inc.30DPlus Therapeutics, Inc.38DRadiko Holdings Corp——Petros Pharmaceuticals, Inc.47DRegenerative Medical Technology Group Inc.36DNeighbors
Broward →Key facts
CEOIan T. Bothwell
SectorHealthcare
IndustryBiotechnology
HeadquartersDavie, FL
ExchangeOTC: ZEOX
Employees20
IPO date2016-03-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.